Treatment of autism spectrum disorder and associated symptoms
OwnerRichard Louis Priceinventor
Life of this patent
Estimating the term…
Abstract
Disclosed is a single unit oral dosage form having, in combination, inositol and an extended release clonidine or extended release guanfacine. In one aspect, a method for treating ADHD and/or associated symptoms thereof includes administering to an ADHD patient the single unit oral dosage form. In another aspect, a method for treating ADHD and/or associated symptoms thereof includes administering to an ADHD patient inositol in combination with extended release clonidine or extended release guanfacine, whether administered separately or as a single dosage form.
Claims14
A method for treating a patient having core symptoms of autism spectrum disorder (ASD), the method comprising administering to the patient one or more single unit oral dosage forms per day, each of the one or more single unit dosage forms comprising, in combination, inositol and an extended release clonidine or extended release guanfacine, wherein the inositol is cumulatively provided in an amount of at least 12,000 mg per day and wherein the method treats the patient's core symptoms of ASD.
A method for treating a patient having core symptoms of autism spectrum disorder (ASD), the method comprising administering to the patient one single unit oral dosage form per day, the dosage form comprising, in combination, inositol and an extended release clonidine or extended release guanfacine, wherein the inositol is present in the dosage form in an amount of from 12,000 mg to 32,400 mg and wherein the method treats the patient's core symptoms of ASD.
Dependencies are inferred from the claim text.